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INTRODUCTION
Heme oxygenase (HO) is the rate limiting enzyme for the
breakdown of heme to generate carbon monoxide, iron, and
biliverdin. Biliverdin is rapidly converted to bilirubin by bi-
liverdin reductase (1). Experimental evidence suggests that
the induction of HO-1, the inducible isoform of HO, is an
important endogenous mechanism for cytoprotection and the
downstream products of heme degradation may mediate the
beneficial effects, such as antioxidant, anti-inflammatory prop-
erties, etc (1). Induction of HO-1 has also been demonstrat-
ed to lower blood pressure in several animal models, includ-
ing the spontaneous hypertensive rat (SHR) and experimen-
tal renovascular hypertension, as well as in angiotensin II-de-
pendent hypertension (2-10). However, the mechanism by
which HO-1 induction lowers blood pressure has not been
fully verified. One possible mechanisms is decreasing vascu-
lar resistance by the HO-driven carbon monoxide (8, 9, 11).
HO-1 also plays a crucial role in significant attenuation of
angiotensin II-medicated tubulointerstitial injury and salt-
resistant hypertension (6). An additional possible anti-hyper-
tensive process linked to the induction of HO-1 is the anti-
oxidant activity of heme degradation products. Reactive oxy-
gen species (ROS) have been known to be an important fac-
tor in the pathogenesis of hypertension (12). The increased
ROS production in the renal medulla is a key component of
angiotensin II-dependent hypertension (13). Renal medullary
superoxide production generated by angiotensin II infusion
to the animal model is normalized with decreased blood pres-
sure by pretreatment with HO-1 inducer (7). The major mech-
anism by which HO-1 induction reduces ROS is through the
generation of bilirubin, a potent antioxidant (14). Increased
levels of bilirubin can prevent the pressor actions of angiotensin
II through the scavenging of superoxide anions in the vascu-
lature (15) and also inhibit NADPH oxidase (16) and protein
kinase C activity (17), both of which mediate angiotensin II-
induced vascular injury (18).
In humans, the effects of mildly increased serum bilirubin
levels have been reported to be a decreased risk for the devel-
opment of coronary artery disease and atherosclerosis (19).
However, few human studies have demonstrated the relation-
ship between serum bilirubin level and the development of
hypertension. In one study with a small subject sample, serum
bilirubin level was lower in 34 untreated hypertensive sub-
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The Bilirubin Level is Negatively Correlated with the Incidence of
Hypertension in Normotensive Korean Population
Reactive oxygen species have been known to be an important factor in the patho-
genesis of hypertension. Bilirubin, one of the metabolites of heme degraded by heme
oxygenase, is a potent anti-oxidant. We verified the effect of serum bilirubin level on
the incidence of hypertension in normotensive subjects. We grouped 1,208 normoten-
sive subjects by the criterion of the highest quintile value of serum bilirubin, 1.1 mg/dL.
The incidence of hypertension was higher in group 1 with bilirubin less than 1.1 mg/
dL than in group 2 with bilirubin 1.1 mg/dL or more (186/908 vs. 43/300, p=0.018).
The relative risk for hypertension was 0.71 (95% confidence interval, 0.51-0.99),
p=0.048 in group 2 compared to group 1 by Cox’s proportional hazard model.
Among the groups stratified by gender, smoking, and liver function status, the
group 2 showed a lower risk of hypertension in females and in non-smokers. In
conclusion, a mild increase within the physiological range of serum bilirubin con-
centration was negatively correlated with the incidence of hypertension. The effect
of bilirubin on the development of hypertension was more evident in females and
in non-smokers.
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jects compared to 272 normotensive and 89 treated hyperten-
sive subjects (20). The bilirubin level was not different between
the normotensive and treated hypertensive subjects (20).
In the present study, we investigated the relationship between
serum bilirubin level and the incidence of hypertension in
normotensive subjects who had undergone repeated routine
health check-ups. We also analyzed the data in subgroups
stratified with possible important confounding factors affect-
ing serum bilirubin levels, such as gender, hepatic function-
al status, and status of smoking (21).
MATERIALS AND METHODS
Study subjects
The institutional review board had approved this study.
The 3, 668 study candidates aged 18 yr or more had under-
gone routine health check-ups twice or more during the 10-
yr period from September 1995 to August 2005 in the out-
patient clinic at the health promotion center of Seoul Nation-
al University Hospital, Seoul, Korea. Among them, we select-
ed 1, 208 subjects with systolic blood pressure less than 120
mmHg and diastolic blood pressure less than 80 mmHg who
had not taken any anti-hypertensive medicine on the first health
check-up (Fig. 1). The selected subjects had undergone health
check-ups a mode of 3 times (range: 2-12 times) at an inter-
val of 8 months (range 4-51 months) during 129 months.
Clinical data 
The subjects filled up the questionnaires by themselves
about their smoking habit, amount, intake habit, and history
of medical diseases, such as hypertension and diabetes mel-
litus. Blood samples for laboratory tests were taken after 12 hr
fasting. The following information was obtained from elec-
tronic medical records as well as the questionnaire items: hei-
ght, weight, age, sex, history of diabetes mellitus, medication
for diabetes mellitus, history of hypertension, antihyperten-
sive medication, blood pressure, serum total bilirubin, ala-
nine transaminase (ALT), aspartate aminotransferase (AST),
anti-hepatitis B virus surface antigen, anti-hepatitis B virus
surface antibody, anti-hepatitis C virus antibody, serum glu-
cose, serum albumin, serum uric acid, serum cholesterol, serum
triglyceride, serum high density lipoprotein (HDL) choles-
terol, C-reactive protein, serum creatinine, and the findings
of urinalysis by dipstick and microscopy. Medical history and
blood pressure were also taken and physical examination was
performed by physicians at the health promotion center. The
blood pressure was measured once in the sitting position after
5 min resting using a mercury sphygmomanometer. The
systolic pressure was measured when the first sound was heard
at the beginning of phase I of Korotkoff sound. The diastolic
pressure was measured from the moment the sound could not
be heard at the end of phase IV of Korotkoff sound. In some
case, such as subjects with aortic regurgitation, the muffling
of phase IV Korotkoff sound continued at the lowest level.
In that case, we took the diastolic blood pressure at the begin-
ning of phase IV of Korotkoff sound.
We defined newly developed hypertension as systolic blood
pressure 140 mmHg or more, diastolic blood pressure 90
mmHg or more, or newly taken anti-hypertensive medicine.
We also defined the proteinuria as 2+or more by the urinary
dipstick test and hematuria as 5 or more RBCs in the spun
urine sample observed by light microscopy at 400-times mag-
nification. We defined liver dysfunction as ALT 40 U/L or
more or AST 40 U/L or more. 
Statistical analysis
The SPSS (SPSS version 12.0, Chicago, IL, U.S.A.) pack-
age was used for statistical analysis. The quintile values of
serum bilirubin in the 1, 208 subjects were 0.6 mg/dL, 0.8
mg/dL, 1.0 mg/dL, and 1.1 mg/dL and we grouped the sub-
jects according to the highest quintile value of serum biliru-
bin 1.1 mg/dL. Differences in proportions among the subject
groups were compared by the Pearson’s chi-square test. Group
differences for continuous variables were assessed by the Stu-
dent t-test. We defined the event period as the duration from
the date of the first health check-up to the date when subjects
had become hypertensive during follow-up health check-up
(s). We compared the cumulative incidence of hypertension
between the bilirubin groups by Log-rank test. To determine
whether the bilirubin category was associated independently
with the incidence of hypertension, we used Cox’s proportion-
al hazard model adjusted for serum albumin and univariate
risk factors for the development of hypertension. We checked
the violation of the proportional hazard assumption by par-
tial residual plot against time for each covariate and log minus
log plots (LML) for categorical covariates, such as bilirubin
group. The average values of residuals for covariates includ- Fig. 1. Selection of study subjects.
Search the database of
the health check-up records,
computerized in
electronic medical record
during last 10 yr
Selected 1,208 subjects,
aged more than 18 yr,
who did not take anti-hypertensive medicine,
SBP less than 120 mmHg, and
DBP less than 80 mmHg at the fist examination
Exclude 23 candidates because of
absence of bilirubin result
3,656 candidates,
aged more than 18 yr,
who had taken
repeated examinationsS52 H.J. Chin, Y.R. Song, H.S. Kim, et al.
ed in Cox’s model were zero and the LML for each categori-
cal variable was parallel. Two-sided p values are reported, with
0.05 taken as the level of statistical significance. All data are
shown as mean±standard deviation or frequency per obser-
vation.
RESULTS
Subject characteristics at initial examination
A total of 605 males and 603 females, aged 47.1±9.0 yr,
were enrolled. Group 1 included 908 subjects and group 2
included 300 subjects. The frequency of females was higher
in group 1 than in group 2. In group 1, the levels of mean
blood pressure, systolic blood pressure, serum ALT, serum
uric acid, serum albumin and serum creatinine were lower
than in group 2 (Table 1). The differences of these clinical
parameters between the two groups were mainly due to the
gender discrepancy between the groups, as confirmed by the
absence of these differences after the subjects were stratified
by gender. The current smoking rate of the subjects was not
different between the groups. There were no differences in
the presence of hepatitis B virus surface antigenemia and
anti-hepatitis C virus antibody. The frequency of liver dys-
function was slightly, but not significantly, higher in group
2 than in group 1.
The incidence of hypertension
During health check-ups, hypertension was developed in
229 out of 1, 208 subjects (19.0%). The incidence of hyper-
tension was significantly higher in group 1 than in group 2
(186/908 vs. 43/300, p=0.018). Kaplan-Meier analysis also
showed that the cumulative incidence of hypertension was
higher in group 1 than in group 2 (Fig. 2). 
The subgroup which developed hypertension showed high-
er frequencies of male and diabetes mellitus. The initial val-
ues of age, mean arterial blood pressure, systolic blood pres-
sure, diastolic blood pressure, serum creatinine, fasting serum
glucose, serum uric acid, serum cholesterol, serum triglyc-
eride, C-reactive protein (CRP), and AST were higher, while
Group 1, subjects with bilirubin less than 1.1 mg/dL at initial examination; Group 2, subjects with bilirubin 1.1 mg/dL or more at initial examination; BMI,
body mass index. MBP, mean arterial blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, Alanine transaminase; AST,
Aspartate aminotransferase; HBV surface antigen, hepatitis B virus surface antigen; Anti-HBs antibody, anti-hepatitis B virus surface antigen antibody;
Anti-HCV antibody, Anti-hepatitis C virus antibody; liver dysfunction, subjects with ALT 40 U/L or more or AST 40 U/L or more; HDL-C, high density
lipoprotein cholesterol; proteinuria, urine protein 2+ or more by dipstick test; hematuria, urine RBC 5 or more/HPF by microscopic examination (×400).
Bilirubin groups Completeness
of data (%) Group 1 (n=908) Group 2 (n=300) p
Age (yr) 100.0 47.1±8.9 47.2±9.0 0.88
Gender (female %) 100.0 56.3 30.7 <0.001
Habit of smoking (current %) 95.4 28.5 31.8 0.27
Diabetes Mellitus (%) 100.0 6.2 4.3 0.24
BMI (kg/m
2) 100.0 23.3±2.7 23.1±2.7 0.47
MBP (mmHg) 100.0 81±68 2 ±6 <0.05
SBP (mmHg) 100.0 107±9 108±8 <0.05
DBP (mmHg) 100.0 68±76 9 ±7 0.06
Total bilirubin (mg/dL) 100.0 0.74±0.17 1.38±0.65 <0.001
AST (U/L) 100.0 22.4±8.2 23.4±10.5 0.12
ALT (U/L) 100.0 22.4±13.8 25.0±18.3 <0.05
HBV surface Antigen (%) 100.0 5.2 8.0 0.07
Anti-HBs antibody (%) 100.0 71.1 65.3 0.06
Anti-HCV antibody (%) 97.6 0.8 1.4 0.34
Liver dysfunction (%) 97.6 9.7 13.3 0.08
Uric acid (mg/dL) 100.0 4.68±1.29 5.27±1.29 <0.001
Fasting glucose (mg/dL) 100.0 94.3±21.1 93.8±18.7 0.70
Protein (g/dL) 100.0 7.37±0.40 7.41±0.40 0.08
Albumin (g/dL) 100.0 4.32±0.26 4.41±0.29 <0.001
Cholesterol (mg/dL) 100.0 197.6±35.5 196.1±30.8 0.53
Triglyceride (mg/dL) 100.0 111.8±68.1 108.2±60.2 0.39
HDL-C (mg/dL) 100.0 53.9±14.3 54.3±14.1 0.66
CRP (mg/dL) 97.8 0.18±0.41 0.15±0.18 0.11
Creatinine (mg/dL) 99.8 0.86±0.16 0.94±0.16 <0.001
Proteinuria (%) 99.0 2.0 3.0 0.30
Hematuria (%) 99.0 8.0 7.1 0.60
Table 1. The baseline characteristics of subjectsBilirubin and Hypertension S53
the values of HDL cholesterol, and serum bilirubin were
lower in subjects who developed hypertension than in the
normotensive subjects (Table 2). Biliurbin group 2 had a
lower risk to develop hypertension than group 1 after partial
or full adjustment for serum albumin and univariate factors.
The relative risk (RR) for the development of hypertension
was 29% lower in group 2 than in group 1 (Table 3). The
other risk factors to the development of hypertension were
older age (yr) (RR, 1.03 [95% confidence interval (CI), 1.01-
1.04], p<0.001), presence of diabetes mellitus (RR, 1.99 [95%
CI, 1.31-3.02], p=0.001), higher body mass index (BMI,
kg/m2) (RR, 1.11 [95% CI, 1.06-1.16], p<0.001), and higher
level of systolic blood pressure (mmHg) (RR, 1.05 [95%
CI, 1.02-1.07], p<0.001).
Incidence of hypertension in the stratified subgroups
The difference of cumulative incidence of hypertension acco-
rding to bilirubin level was significant in the female group
but not in the male group (Fig. 3). In females, RR for the devel-
opment of hypertension was 0.39 (95% CI, 0.17-0.91, p=
0.028) in bilirubin group 2 compared to bilirubin group 1 by
Cox’s proportional hazard model adjusted for serum albumin
and independent risk factors of age, body mass index, systolic
blood pressure, history of diabetes mellitus, and serum uric
acid level 
In the subjects with liver dysfunction, the bilirubin level
was not associated with the incidence of hypertension, whereas
in the subjects without liver dysfunction, the incidence of
Fig. 2. The probability of normotension in subjects. Group 1, sub-
jects with initial bilirubin less than 1.1 mg/dL; Group 2, subjects with
initial bilirubin 1.1 mg/dL or more. Number under the graph, sub-
jects’ number at the given period.
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Group 1; subjects with bilirubin less than 1.1 mg/dL at initial examination;
Group 2; subjects with bilirubin 1.1 mg/dL or more at initial examination.
BMI, body mass index; MBP, mean arterial blood pressure; SBP, systolic
blood pressure; DBP, diastolic blood pressure; ALT, Alanine transami-
nase; AST, Aspartate aminotransferase; HBV surface antigen, hepatitis
B virus surface antigen; Anti-HBs antibody, anti-hepatitis B virus surface
antigen antibody; Anti-HCV antibody, Anti-hepatitis C virus antibody; liver
dysfunction, subjects with ALT 40 U/L or more or AST 40 U/L or more;
HDL-C, high density lipoprotein cholesterol; proteinuria, urine protein 2+
or more by dipstick test; hematuria, urine RBC 5 or more/HPF by micro-
scopic examination (×400).
Subjects Subjects
remained developed
p
normotension hypertension
(n=979) (n=229)
Age (yr) 46.5±8.8 49.8±9.4 <0.001
Gender (female %) 51.7 42.4 <0.05
Habit of smoking (current %) 28.8 31.5 0.43
Diabetes Mellitus (%) 4.2 12.2 <0.001
BMI (kg/m
2) 23.0±2.6 24.4±2.9 <0.001
MBP (mmHg) 81±68 4 ±5 <0.001
SBP (mmHg) 107±9 110±7 <0.001
DBP (mmHg) 68±77 1 ±6 <0.001
Total bilirubin (mg/dL) 0.91±0.48 0.85±0.31 <0.05
AST (U/L) 22.8±9.2 23.2±7.0 0.17
ALT (U/L) 22.6±15.5 25.0±12.9 <0.05
HBV surface Antigen (%) 5.5 7.4 0.27
Anti-HBs antibody (%) 70.3 67.2 0.37
Anti-HCV antibody (%) 0.9 0.9 1.00
Liver dysfunction (%) 9.8 14.0 0.07
Uric acid (mg/dL) 4.75±1.30 5.14±1.30 <0.001
Fasting glucose (mg/dL) 93.2±17.7 98.2±29.4 <0.05
Protein (g/dL) 7.38±0.39 7.37±0.42 0.70
Albumin (g/dL) 4.34±0.26 4.37±0.28 0.12
Cholesterol (mg/dL) 195.6±33.4 204.4±37.4 <0.01
Triglyceride (mg/dL) 107.6±63.7 124.7±74.5 <0.001
HDL-C (mg/dL) 54.5±14.3 51.5±13.7 <0.01
CRP (mg/dL) 0.16±0.31 0.22±0.54 <0.05
Creatinine (mg/dL) 0.87±0.16 0.91±0.16 <0.01
Proteinuria (%) 2.0 3.5 0.15
Hematuria (%) 7.6 8.4 0.70
Table 2. The univariate risk factors to the development of hyper-
tension during follow-up examination
*Partially adjusted with age, gender, liver dysfunction, and serum albumin; 
� Fully adjusted with age, gender, diabetes mellitus, BMI, systolic blood pres-
sure, diastolic blood pressure, serum uric acid, serum cholesterol, serum HDL cholesterol, serum triglyceride, CRP, serum creatinine, Bilirubin Group
1: subjects with bilirubin less than 1.1 mg/dL at initial examination, Bilirubin Group 2: subjects with bilirubin 1.1 mg/dL or more at initial examination.
B Wald p
Relative risk (RR)
[95% CI of RR]
Bilirubin Group 2 (compared to Group 1)* -0.384 4.984 0.026 0.68 (0.49-0.96)
Bilirubin Group 2 (compared to Group 1)
� -0.342 3.921 0.048 0.71 (0.51-0.99)
Table 3. The Cox’s hazard proportional analysis for the risk factors to the development of hypertension during follow-up examinationS54 H.J. Chin, Y.R. Song, H.S. Kim, et al.
hypertension was lower in the bilirubin group 2 than in the
bilirubin group 1 (35/260 vs. 162/820, p=0.022). The cumu-
lative incidence of hypertension in subjects without liver dys-
function was also lower in group 2 than in group 1 but the
bilirubin group was not an independent risk factor to hyper-
tension by Cox’s proportional hazard model.
The bilirubin level was not associated with the incidence
of hypertension in current smokers, whereas in non-smokers,
bilirubin group 2 had lower risk of hypertension than group
1 (Log rank test, p=0.023). In non-smokers, RR for hyper-
tension in group 2 was 0.53 (95% CI, 0.34-0.82, p=0.005)
adjusted with independent risk factors to hypertension com-
pared to group 1. 
DISCUSSION
The concentration of serum bilirubin is affected by gender,
smoking status, fasting status, as well as diseased conditions.
In a previous report, the individual changes in serum biliru-
bin concentration due to fasting averaged 0.18 mg/dL for
women and 0.24 mg/dL for men (fasting values minus non-
fasting values) (22). The serum bilirubin level is lower in fe-
males than in males (22, 23) and is lower in current smokers
than in ex-smokers or non-smokers (21, 23). In this study,
subjects were instructed to fast for at least 12 hr before blood
sampling and we assumed that the serum bilirubin levels were
measured after a similar fasting period among the subjects.
We stratified the data according to the factors of gender, cur-
rent smoking, and liver dysfunction status in order to elimi-
nate the confounding factors which affect serum bilirubin co-
ncentration. 
The subjects with higher bilirubin level showed a lower in-
cidence of hypertension than did the subjects with lower biliru-
binlevel, especially in females and in non-smokers.
In an animal hypertensive model using hyperbilirubinemic
Gunn rats infused with angiotensin II, the rise in systolic blood
pressure was markedly blunted compared to that in control
rats (15). The oxidative stress was attenuated in the Gunn rat
and in the aortic rings from angiotensin II-infused rats by
bilirubin (15). Increased ROS has been demonstrated in the
SHR (24), DOCA-salt hypertensive (25), and Dahl salt-sen-
sitive rats (26), as well as in hypertension induced by angio-
tensin II (27). In humans, enhanced production of superox-
ide and hydrogen peroxide has been demonstrated in untreat-
ed individuals with mild to moderate hypertension. This abnor-
mality can be reversed by the control of hypertension with beta
blockers or ACE inhibitors (28). Thus, mild hyperbilirubine-
mia may have, at least in part, an anti-hypertensive role by
the quenching of oxidative stress (15). 
The bilirubin group was a risk factor to the development
of hypertension only in the non-smokers. Bilirubin is an endo-
genous antioxidant and is destroyed by ROS (14). Smoking
generates free radical species (29) which might consume the
serum antioxidant, bilirubin, and enhance UDP-glucuronyl-
transferase activity (30) which is inversely related to serum
bilirubin concentration. Smoking itself also increases blood
pressure and aortic stiffness in humans (31). Therefore, the
antioxidant effect of bilirubin can be decreased in the high-
er level of free radicals generated by current smoking and the
potential anti-hypertensive capacity of bilirubin might be also
reduced. In, this study, the rate of current smoking was much
Fig. 3. The probability of normotension according to gender. Group 1, subjects with initial bilirubin less than 1.1 mg/dL; Group 2, subjects
with initial bilirubin 1.1 mg/dL or more. (A) Kaplan-Meier analysis in female subjects. (B) Kaplan-Meier analysis in male subjects. Number
under the graph: subjects’ number at the given period.
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higher in males than in females, which is a possible explana-
tion for why the relationship between bilirubin and hyper-
tension incidence was evident only in females. The other pos-
sible explanation for the different effect of bilirubin on the
development of hypertension between genders is the sex-dif-
ference of HO activity to stress. Trauma and hemorrhage dou-
bled the hepatic HO-1 expression in female rats compared
with male rats (32).
Subjects with liver dysfunction had more risk factors to
develop hypertension, such as higher BMI, higher frequency
of diabetes mellitus, and higher rate of hyperuricemia, com-
pared to subjects with normal liver function (data not shown).
The bilirubin effect on the development of hypertension may
have been overwhelmed by those risk factors in subjects with
liver dysfunction. In subjects with normal liver function, biliru-
bin effect on the hypertension was not consistent and depen-
dent on the specific criterion of bilirubin. The criterion of
0.9 mg/dL was significant (data were not shown) but 1.1 mg/
dL was not a risk factor to hypertension. So, there might be
some other statistical or clinical confounding factors when we
confine the group to the subjects with normal liver function.
A serum bilirubin level of 10 μ M/L was suggested as a cut-
point for the discrimination of cardiovascular risk but other
cut-points have been proposed in other studies (19). In this
study, the serum bilirubin level assigned to discriminate the
risk of hypertension was 1.1 mg/dL. It seemed that the appro-
priate bilirubin level to discriminate the risk of hypertension
might be different in clinical situations because the bilirubin
group with the criterion of 0.9 mg/dL in the non-smokers also
the independent risk factor to the incidence of hypertension,
which was lower than the criterion of 1.1 mg/dL in whole
subjects (data were not shown). That implies a relatively lower
level of bilirubin would be sufficient to protect the develop-
ment of hypertension in subjects with a lower risk of hyper-
tension.
This study suffered several limitations. Firstly, blood pres-
sure was measured just once in the sitting position using a
mercury sphygmomanometer. We asked subjects about their
smoking habit, duration of smoking, and amount of smok-
ing but could only get information on the smoking habit
(current smoker or non-current smoker) at a reasonable rate
among the subjects. We therefore could not analyze the effect
of duration and smoking amount on the development of hyper-
tension. Although the subjects were asked to fast for at least
12 hr before the blood tests, we did not confirm the exact fast-
ing period before the measurement of serum bilirubin con-
centration. We used the unit of mg/dL for serum bilirubin
concentration although the SI units (μ M/L) are more infor-
mative and better able to discriminate serum bilirubin lev-
els within the physiological range (19). We did not have infor-
mation about age at menopause and estrogen replacement ther-
apy in women which could affect on the development of hyper-
tension. But, the mean age of female was not different between
two bilirubin groups (p=0.072) and the number of females
aged more than 47 yr, which is the mean age at menopause
in Korean women (33), was not different between bilirubin
groups, either (p=0.086). In younger subjects aged less than
50 yr, RR for the development of hypertension was 0.605
(95% CI, 0.372-0.984, p=0.043) in bilirubin group 2 com-
pared to bilirubin group 1 and, in older subjects aged 50 yr
or more, RR for the development of hypertension was not
different between bilirubin groups (p=0.299). Although we
could not assure whether the menopause and the estrogen
replacement therapy were confounding factors to the relation-
ship between bilirubin group and the incidence of hyperten-
sion in older subjects, the bilirubin effect on the hypertension
was at least meaningful in younger subjects.
In conclusion, a mild increase within the physiological range
of serum bilirubin concentration was negatively correlated
with the incidence of hypertension in subjects with normal
blood pressure. The effect of bilirubin on the development of
hypertension was more evident in females and in non-smokers.
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